In a clinical study, researchers evaluated cDC1 vaccine pulsed with HER-2 peptide in early invasive breast cancer (IBC) and ductal carcinoma in situ (DCIS) (Lowenfeld et al., 2017). Here, ERBB2 is linked to ductal breast carcinoma in situ.